Cite
Vilaprisan, a New Selective Progesterone Receptor Modulator in Uterine Fibroid Pharmacotherapy-Will it Really be a Breakthrough?
MLA
Ciebiera, Michal, et al. “Vilaprisan, a New Selective Progesterone Receptor Modulator in Uterine Fibroid Pharmacotherapy-Will It Really Be a Breakthrough?” Current Pharmaceutical Design, vol. 26, no. 3, 2020, pp. 300–09. EBSCOhost, https://doi.org/10.2174/1381612826666200127092208.
APA
Ciebiera, M., Vitale, S. G., Ferrero, S., Vilos, G. A., Barra, F., Caruso, S., Laganà, A. S., Sierant, A., Cianci, A., & Jakiel, G. (2020). Vilaprisan, a New Selective Progesterone Receptor Modulator in Uterine Fibroid Pharmacotherapy-Will it Really be a Breakthrough? Current Pharmaceutical Design, 26(3), 300–309. https://doi.org/10.2174/1381612826666200127092208
Chicago
Ciebiera, Michal, Salvatore G Vitale, Simone Ferrero, George A Vilos, Fabio Barra, Salvatore Caruso, Antonio S Laganà, Antoni Sierant, Antonio Cianci, and Grzegorz Jakiel. 2020. “Vilaprisan, a New Selective Progesterone Receptor Modulator in Uterine Fibroid Pharmacotherapy-Will It Really Be a Breakthrough?” Current Pharmaceutical Design 26 (3): 300–309. doi:10.2174/1381612826666200127092208.